Literature DB >> 16897791

The new Swedish Prescribed Drug Register--opportunities for pharmacoepidemiological research and experience from the first six months.

Björn Wettermark1, Niklas Hammar, Carl Michael Fored, C MichaelFored, Andrejs Leimanis, Petra Otterblad Olausson, Ulf Bergman, Ingemar Persson, Anders Sundström, Barbro Westerholm, Måns Rosén.   

Abstract

PURPOSE: To describe the content and potentials of the new Swedish national register on prescribed and dispensed medicines.
METHODS: The Swedish Prescribed Drug Register contains information about age, sex and unique identifier of the patient as well as the prescriber's profession and practice. Information regarding drug utilization and expenditures for prescribed drugs in the entire Swedish population was extracted from the first six months July-December 2005 and compared with total drug sales in the country including OTC and hospital use.
RESULTS: The total quantity of drugs sold in Sweden was 2666 million DDDs, corresponding to 1608 DDD/1000 inhabitants daily. The total expenditures were 1.6 billion Euro. The prescribed drugs, included in the register, accounted for 84% of the total utilization and 77% of the total expenditures. About half of all men and two-thirds of all women in the country purchased drugs. The proportion increased by age. The most common drugs for chronic treatment were diuretics among women (8.8% of the population) and antithrombotic agents among men (7.6%). Psychotropic drugs, corticosteroids and analgesics were more common among women, while men used antithrombotic agents, antidiabetic drugs, lipid lowering agents and ACE inhibitors to a greater extent.
CONCLUSIONS: The new register provides valuable data on exposure to drugs and is useful to study patterns of drug utilization. The possibilities for record linkage to other health registers gives from an international perspective good opportunities to explore drug and disease associations and the risks, benefits, effectiveness and health economical effects of drug use.

Entities:  

Mesh:

Year:  2007        PMID: 16897791     DOI: 10.1002/pds.1294

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  536 in total

1.  High concomitant use of interacting drugs and low use of gastroprotective drugs among NSAID users in an unselected elderly population: a nationwide register-based study.

Authors:  Rickard Ljung; Yunxia Lu; Jesper Lagergren
Journal:  Drugs Aging       Date:  2011-06-01       Impact factor: 3.923

2.  Impact of the drug-drug interaction database SFINX on prevalence of potentially serious drug-drug interactions in primary health care.

Authors:  M L Andersson; Y Böttiger; J D Lindh; B Wettermark; B Eiermann
Journal:  Eur J Clin Pharmacol       Date:  2012-07-01       Impact factor: 2.953

3.  Low persistence of anticholinergic drug use in Sweden.

Authors:  Love Linnér; Helena Schiöler; Eva Samuelsson; Ian Milsom; Fredrik Nilsson
Journal:  Eur J Clin Pharmacol       Date:  2011-05       Impact factor: 2.953

4.  No association between macrolide treatment in infancy and later pyloric stenosis in Sweden.

Authors:  Jonas F Ludvigsson; Cecilia Lundholm; Anne K Örtqvist; Catarina Almqvist
Journal:  Eur J Epidemiol       Date:  2015-12-22       Impact factor: 8.082

5.  Influence of baseline low-density lipoprotein cholesterol values on statin therapy persistence.

Authors:  Anna Citarella; Marie Linder; Helle Kieler; Ingegärd Anveden Berglind; Anders Sundström; Björn Wettermark; Morten Andersen
Journal:  Eur J Clin Pharmacol       Date:  2015-12-16       Impact factor: 2.953

6.  Stimulant ADHD medication and risk for substance abuse.

Authors:  Zheng Chang; Paul Lichtenstein; Linda Halldner; Brian D'Onofrio; Eva Serlachius; Seena Fazel; Niklas Långström; Henrik Larsson
Journal:  J Child Psychol Psychiatry       Date:  2013-10-25       Impact factor: 8.982

7.  The Risk of Treatment-Emergent Mania With Methylphenidate in Bipolar Disorder.

Authors:  Alexander Viktorin; Eleonore Rydén; Michael E Thase; Zheng Chang; Cecilia Lundholm; Brian M D'Onofrio; Catarina Almqvist; Patrik K E Magnusson; Paul Lichtenstein; Henrik Larsson; Mikael Landén
Journal:  Am J Psychiatry       Date:  2016-10-03       Impact factor: 18.112

8.  Sex differences in spontaneous reports on adverse bleeding events of antithrombotic treatment.

Authors:  Diana M Rydberg; Lennart Holm; Stefan Mejyr; Desirée Loikas; Karin Schenck-Gustafsson; Mia von Euler; Björn Wettermark; Rickard E Malmström
Journal:  Eur J Clin Pharmacol       Date:  2013-10-06       Impact factor: 2.953

9.  Palivizumab Exposure and the Risk of Autoimmune Disease: A Cross-National Cohort Study.

Authors:  Ann Haerskjold; Marie Linder; Lonny Henriksen; Simon Francis Thomsen; Helle Kieler; Henrik Ravn; Lone Graff Stensballe
Journal:  Paediatr Drugs       Date:  2016-12       Impact factor: 3.022

10.  Medicine-taking behaviour and drug-related problems in adolescents of a Swedish high school.

Authors:  Michael Westerlund; Jan-Olof Brånstad; Tommy Westerlund
Journal:  Pharm World Sci       Date:  2007-11-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.